Chinese biomedical producer Shanghai Haohai priced its Hong Kong initial public offering at the top of its range on Friday, raising HK$2.71 billion ($305 million) including the greenshoe. The company benefited from a combination of clear primary markets and strong secondary market momentum to achieve a premium valuation.
¬ Haymarket Media Limited. All rights reserved.
